What is Pathios Therapeutics?
Founded in 2017, Pathios Therapeutics operates at the intersection of advanced cellular immunology and pharmaceutical innovation. The company specializes in the identification and development of novel small-molecule modulators targeting GPR65, a critical innate immune checkpoint. By utilizing a sophisticated platform that integrates transcriptomics and human genetic data, Pathios aims to transform the treatment paradigm for a broad spectrum of cancers and other serious diseases.
The company's market position is defined by its rigorous scientific methodology and its ability to bridge the gap between academic discovery and clinical application. Through a combination of internal expertise and strategic external partnerships, Pathios is effectively navigating the complexities of GPCR drug discovery, positioning itself as a high-potential player in the next generation of immune-oncology therapeutics.
How much funding has Pathios Therapeutics raised?
Pathios Therapeutics has raised a total of $8.8M across 1 funding round:
Series A
$8.8M
Series A (2019): $8.8M with participation from Medical Research Commercialisation Fund and Canaan
Key Investors in Pathios Therapeutics
Medical Research Commercialisation Fund
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, specializing in transforming biomedical research discoveries into medical products that enhance patient outcomes and save lives.
Canaan
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
What's next for Pathios Therapeutics?
Looking ahead, the infusion of capital will be directed toward advancing the company's lead programs through the drug discovery lifecycle. The strategic roadmap involves scaling internal capabilities to validate GPR65 modulators in preclinical models, with the ultimate goal of transitioning these candidates into clinical development. As the company matures, it is expected to leverage its proprietary insights to explore additional therapeutic indications, potentially broadening its impact beyond oncology.
The focus remains on maintaining operational efficiency while accelerating the delivery of novel therapeutic agents. With a robust foundation of institutional support, Pathios is poised to capitalize on the latest advancements in GPCR signaling, ensuring that its scientific output translates into tangible clinical value for patients worldwide.
